Tag Archives: Hartaj Singh

Oppenheimer Thinks SELLAS Life Sciences Group Inc’s Stock is Going to Recover

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS – Research Report), with a price target of $13. The company’s shares opened today at $1.02, close to its 52-week

Alexion Pharmaceuticals (ALXN) Receives a Buy from Oppenheimer

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Alexion Pharmaceuticals (ALXN – Research Report), with a price target of $165. The company’s shares closed yesterday at $131.66. Singh observed: “Alexion (ALXN) presented a comprehensive

Analysts Are Bullish on Top Healthcare Stocks: Cellectis SA (CLLS), VBI Vaccines (VBIV)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cellectis SA (CLLS – Research Report) and VBI Vaccines (VBIV – Research Report) with bullish sentiments. Cellectis SA (CLLS) Oppenheimer analyst Hartaj

Oppenheimer Sticks to Its Buy Rating for Sunesis Pharma (SNSS)

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Sunesis Pharma (SNSS – Research Report). The company’s shares closed yesterday at $0.95. According to TipRanks.com, Singh is a 3-star analyst with an average return of

Oppenheimer Maintains a Buy Rating on Celsion Corp (CLSN)

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Celsion Corp (CLSN – Research Report). The company’s shares opened today at $2.15. According to TipRanks.com, Singh is a 4-star analyst with an average return of

Oppenheimer Maintains a Buy Rating on Gilead Sciences (GILD)

In a report released today, Hartaj Singh from Oppenheimer maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $85. The company’s shares closed yesterday at $65.02. Singh noted: “Gilead (GILD) recently reported a